Verona Pharma Soars 20.6% on $10B Merger with Merck

Verona Pharma plc (NASDAQ:VRNA) surged 20.62% to $104.77 per share after news of its $10 billion acquisition by Merck. Merck will purchase Verona Pharma’s American Depositary Shares at $107 each, aiming to enhance innovative patient treatments. Verona’s CEO praised the deal as a significant milestone for their COPD treatment advancement with Ohtuvayre. The merger reflects Merck’s commitment to science-led strategies and value-driven growth.

Read more at Yahoo Finance: Verona Pharma (VRNA) Skyrockets 20.6% on $10-Billion Merger Deal with Merck